Search results
Author(s):
Linda Joosten
Added:
1 year ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial.
FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists …
View more
Author(s):
Mohammed Sallam
,
Hossameldin Hassan
,
Derek Connolly
,
et al
Added:
6 months ago
Author(s):
Minh That Ton
,
Tri Huynh Quang Ho
,
Viet Lan Nguyen
,
et al
Added:
1 year ago
Author(s):
Renato D Lopes
Added:
8 months ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Author(s):
Maki Komiyama
,
Moritake Iguchi
,
Hiromichi Wada
,
et al
Added:
10 months ago
Author(s):
Cheng Keat Tan
,
David Bin-Chia Wu
,
Seh Yi Joseph Tan
,
et al
Added:
1 year ago
Author(s):
Eirik Ikdahl
,
Anne Kerola
,
Eli Sollerud
,
et al
Added:
4 months ago
Author(s):
William Herrington
Added:
6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Prioritising Risk in CAD: A Patient-First Discussion
Video Series
Author(s):
Vlado Perkovic
Added:
10 months ago
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median…
View more